Zevalin combination shows positive results for non-Hodgkin's lymphoma

01/17/2008 | RTT News

Zevalin, an investigational radioimmunotherapy, combined with autologous stem cell transplantation and high-dose chemotherapy, had a 70% progression-free survival rate at two years in a Phase 2 study of non-Hodgkin's lymphoma patients who were ineligible for total-body irradiation, Cell Therapeutics announced. The study results will appear in the Journal of Clinical Oncology.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT